Incyte, Eli Lilly Expand Collaboration

Jul 14, 2000

Premium

Incyte Genomics of Palo Alto, Calif., and Eli Lilly of Indianapolis have expanded an agreement to collaborate on accelerating the development of therapeutic proteins. Under the terms of the new agreement, Eli Lilly and Incyte will focus on identifying and selecting secreted molecules that are strong candidates for therapeutic protein development. Eli Lilly will also obtain options to license multiple therapeutic protein patents from Incyte.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

For Fewer Mosquitos

NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.

Lasting Mark

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

To Know What's Wrong

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

This Week in Genome Biology

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.

Featured White Papers

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

Powerful Bioinformatic Support for Specialized Therapeutic Antibody Discovery

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar

14

Featured Webinar

A Multiomics Approach to Defining the Nature of Early Malignant Transformations of the Immune System

In this webinar, Dr. Wendy Béguelin of Weill Cornell Medicine will discuss how she used the BD Rhapsody single-cell RNA-seq platform and YFP floxed reporter mouse models to study how lymphoma-associated mutations disrupt the immune system by affecting GC B-cell states, explaining the biology of initiation of low-grade follicular lymphoma.

Main menu